196 related articles for article (PubMed ID: 19008228)
1. Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis.
Wang S; Yu WM; Zhang W; McCrae KR; Neel BG; Qu CK
J Biol Chem; 2009 Jan; 284(2):913-20. PubMed ID: 19008228
[TBL] [Abstract][Full Text] [Related]
2. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.
Yu WM; Daino H; Chen J; Bunting KD; Qu CK
J Biol Chem; 2006 Mar; 281(9):5426-34. PubMed ID: 16371368
[TBL] [Abstract][Full Text] [Related]
3. Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation.
Eminaga S; Bennett AM
J Biol Chem; 2008 May; 283(22):15328-38. PubMed ID: 18378677
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
Niihori T; Aoki Y; Ohashi H; Kurosawa K; Kondoh T; Ishikiriyama S; Kawame H; Kamasaki H; Yamanaka T; Takada F; Nishio K; Sakurai M; Tamai H; Nagashima T; Suzuki Y; Kure S; Fujii K; Imaizumi M; Matsubara Y
J Hum Genet; 2005; 50(4):192-202. PubMed ID: 15834506
[TBL] [Abstract][Full Text] [Related]
6. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Xu D; Wang S; Yu WM; Chan G; Araki T; Bunting KD; Neel BG; Qu CK
Blood; 2010 Nov; 116(18):3611-21. PubMed ID: 20651068
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Lo FS; Kuo TT; Wang CJ; Kuo MT; Kuo MC
Int J Hematol; 2008 Oct; 88(3):287-290. PubMed ID: 18758896
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Uhlén P; Burch PM; Zito CI; Estrada M; Ehrlich BE; Bennett AM
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2160-5. PubMed ID: 16461457
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
10. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
11. Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Xu D; Zheng H; Yu WM; Qu CK
PLoS One; 2013; 8(5):e63152. PubMed ID: 23675459
[TBL] [Abstract][Full Text] [Related]
12. Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations.
Oishi K; Gaengel K; Krishnamoorthy S; Kamiya K; Kim IK; Ying H; Weber U; Perkins LA; Tartaglia M; Mlodzik M; Pick L; Gelb BD
Hum Mol Genet; 2006 Feb; 15(4):543-53. PubMed ID: 16399795
[TBL] [Abstract][Full Text] [Related]
13. SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Langdon Y; Tandon P; Paden E; Duddy J; Taylor JM; Conlon FL
Development; 2012 Mar; 139(5):948-57. PubMed ID: 22278918
[TBL] [Abstract][Full Text] [Related]
14. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
15. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
16. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
[TBL] [Abstract][Full Text] [Related]
17. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
18. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Miyamoto D; Miyamoto M; Takahashi A; Yomogita Y; Higashi H; Kondo S; Hatakeyama M
Oncogene; 2008 Jun; 27(25):3508-15. PubMed ID: 18223690
[TBL] [Abstract][Full Text] [Related]
19. The Noonan syndrome-associated D61G variant of the protein tyrosine phosphatase SHP2 prevents synaptic down-scaling.
Lu W; Ai H; Xue F; Luan Y; Zhang B
J Biol Chem; 2020 Jul; 295(29):10023-10031. PubMed ID: 32499374
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
Schubbert S; Lieuw K; Rowe SL; Lee CM; Li X; Loh ML; Clapp DW; Shannon KM
Blood; 2005 Jul; 106(1):311-7. PubMed ID: 15761018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
